Sanofi to buy Bioverativ for $11.6 billionSanofi is to buy haemophilia specialist Bioverativ for $11.6 billion, the Financial Times said on Monday (APMHE 56520).
Big Pharma makes strongest start to M&A for decadeThe FT on Tuesday said that healthcare companies have announced almost $30 billion of acquisitions since the beginning of the year in the sector’s strongest start for deal-making in more than a decade, as big pharma scrambles to replace ageing blockbusters by paying top dollar for new medicines.
Cannabis drug slashes severe epilepsy fitsThe Times on Thursday reported that a drug derived from cannabis, developed by GW Pharmaceuticals, can reduce seizures in epilepsy sufferers by nearly half, a study has suggested.
Novartis strikes $170 million deal for non-U.S. rights to gene therapy for blindnessThe FT on Thursday said that Novartis has bought the rights to market a gene therapy for blindness outside the U.S., in a deal that could be worth more than $170 million for Spark Therapeutics, the Philadelphia-based biotech that developed the drug. (APMHE 56584)
Biogen buys brain drugThe FT on Friday reports that Biogen said it would buy an experimental brain drug targeting various neurological conditions in a deal worth up to $217 million, although it stopped short of announcing the sizeable acquisition that some investors had expected.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.